The cord blood banking market is rapidly evolving. Major research advances are announced every month. Innovation is the only constant.
Under these circumstances, it is difficult to track the ever-changing landscape of the cord blood banking market. Therefore, these scholarly research round-ups highlight “must know” research advances occurring in the sector, both those published by extremely well-regarded researchers (such as Joanne Kurtzberg’s article below), as well as those published by up-and-coming scientists.
It is extremely time-consuming to stay on top of the latest cord blood science. However, you don’t need to sort through scholarly journals or waste your time surfing online.
Let us do the hard work for you.
Recovery from neurological injuries is typically incomplete and often results in significant and permanent disabilities. Currently, most available therapies are limited to supportive or palliative measures, aimed at managing the symptoms of the condition…
OTHER MAJOR CORD BLOOD RESEARCH ADVANCES:
1. Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir.
A Vivanti, TS Soheili, W Cuccuini, S Luce, L Mandelbrot… – AIDS, 2015
Zidovudine and tenofovir are the two main nucleos(t)ide analogs used to prevent mother-to-child transmission of HIV. In vitro, both drugs bind to and integrate into human DNA and inhibit telomerase. The objective of the present study was to assess the …
2. Human allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy
3. Human Umbilical Cord Blood Derived Mesenchymal Stem Cells Improve Cardiac Function in CTNTR141W Transgenic Mouse Model of Dilated Cardiomyopathy
4. Stem cell comparison: what can we learn clinically from unrelated cord blood transplantation as an alternative stem cell source?
5. Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells
7. Clinical study on 137 cases of unrelated single unit umbilical cord blood hematopoietic stem cell transplantation
9. The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in rats
Future Cord Blood News
Sign-up below to be alerted as soon as new cord blood market news is posted.
BioInformant is the only research firm that has served the cord blood sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine (CIRM).
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in cord blood industry data.
To learn more about trends and opportunities within the cord blood banking industry, view the “Complete 2015-16 Global Cord Blood Banking Industry Report” now.